1. CANCER TREATMENT REGIMENS
The selection, dosing, and administration of anticancer agents and the management of associated
toxicities are complex. Drug dose modifications and schedule and initiation of supportive care
interventions are often necessary because of expected toxicities and because of individual patient
variability, prior treatment, and comorbidities. Thus, the optimal delivery of anticancer agents
requires a healthcare delivery team experienced in the use of such agents and the management
of associated toxicities in patients with cancer. These cancer treatment regimens may include
both FDA-approved and unapproved uses/regimens and are provided as references only to
the latest treatment strategies. Clinicians must choose and verify treatment options based on the
individual patient.
NOTE: Grey shaded boxes contain updated regimens.
Gastrointestinal Cancers
Anal Cancer
1

2. ANAL CANCER
REGIMEN DOSING
Localized Cancer
5-fluorouracil (5-FU) +
mitomycin (Mutamycin; MTC) +
radiotherapy1, 2
Days 1–4 and Days 29–32: 5-FU 1,000mg/m2
/day plus
Days 1 and 29: Mitomycin 10mg/m2
IV + radiotherapy 45–59Gy (min dose
of 45Gy in 25 fractions of 1.8Gy over 5 weeks).
Metastatic Cancer
5-FU + cisplatin (Platinol; CDDP)1
Days 1–5: 5-FU 1,000 mg/m2
/day IV plus
Day 2: Cisplatin 100mg/m2
IV.
References
1. NCCN Clinical Practice Guidelines in Oncology™.Anal
Carcinoma. v 1.2012.Available at: http://www.nccn.org/
professionals/physician_gls/pdf/anal.pdf.Accessed
October 11, 2011.
2. Ajani JA,Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin,
and radiotherapy vs fluorouracil, cisplatin, and radiotherapy
for carcinoma of the anal canal: a randomized controlled trial.
JAMA. 2008;299(16):1914–1921.
(Revised 11/2011)
Copyright © 2011 by Haymarket Media Inc.
2